Guillermo Servera Negre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Guillermo Servera Negre has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Pedro Herranz Pinto
Department of Dermatology, Hospital Universitario La Paz, Madrid, Spain
3 shared publications Alexis Palpán
Servicio de Neurocirugía, Hospital Universitario La Paz, Madrid, Spain
1 shared publication- Almudena Nuño González
Department of Dermatology La Paz University Hospital Madrid Spain
1 shared publication - Ander Mayor Ibarguren
Servicio de Dermatología Hospital Universitario La Paz Madrid Spain
1 shared publication Ander Paulo Mayor Ibarguren
Department of Dermatology and Venereology, La Paz University Hospital, Madrid, Spain
1 shared publication- Carlos González-Herrada
Dermatology Department, Hospital Universitario de Getafe, 28905 Getafe, Spain
1 shared publication
Latest Publications
- Open Access
- 27 March 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (4) , e70242
Efficacy and Safety of Topical Delgocitinib for Chronic Hand Eczema: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Chronic hand eczema (CHE) is associated with substantial functional impairment and reduced quality of life. Delgocitinib, a pan‐Janus kinase (JAK) inhibitor, has emerged as a promising topical treatment for CHE. A systematic review and meta‐analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy and safety of topical delgocitinib 20–30 mg/g compared with vehicle in patients with CHE. PubMed, Embase, Cochrane Library, ClinicalTrials.gov , EU CTR, and WHO ICTRP were searched up to 15 February 2026. The primary outcome was treatment success at week 16, defined as clear or almost clear skin with a ≥ 2‐point improvement on the Investigator's or Physician's Global Assessment (IGA/PGA). Secondary outcomes included treatment success at weeks 4 and 8, changes in Hand Eczema Symptom Diary (HESD) itch and pain scores, and safety outcomes. Relative risks (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were calculated using random‐effects models. Three publications reporting four RCTs involving 1154 patients were included, with 752 receiving delgocitinib and 402 receiving vehicle. At week 16, treatment success was significantly higher with delgocitinib (RR 3.17; 95% CI 1.78–5.65; p < 0.01), corresponding to an absolute risk difference of 16.9% and a number needed to treat (NNT) of 6 (95% CI 3–16). Similar results at weeks 4 and 8. Delgocitinib also led to significantly greater improvements in HESD itch and pain scores. No significant differences were found in overall adverse events (AEs), treatment‐related AEs, or serious AEs. Discontinuation due to AEs was lower in the delgocitinib group. Delgocitinib 20–30 mg/g demonstrated greater efficacy than vehicle and a favourable safety profile, supporting its use as a topical treatment for CHE.
- 27 March 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (4) , e70242
Open AccessEfficacy and Safety of Topical Delgocitinib for Chronic Hand Eczema: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
Chronic hand eczema (CHE) is associated with substantial functional impairment and reduced quality of life. Delgocitinib, a pan‐Janus kinase (JAK) inhibitor, has emerged as a promising topical treatment for CHE. A systematic review and meta‐analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy and safety of topical delgocitinib 20–30 mg/g compared with vehicle in patients with CHE. PubMed, Embase, Cochrane Library, ClinicalTrials.gov , EU CTR, and WHO ICTRP were searched up to 15 February 2026. The primary outcome was treatment success at week 16, defined as clear or almost clear skin with a ≥ 2‐point improvement on the Investigator's or Physician's Global Assessment (IGA/PGA). Secondary outcomes included treatment success at weeks 4 and 8, changes in Hand Eczema Symptom Diary (HESD) itch and pain scores, and safety outcomes. Relative risks (RRs) and mean differences (MDs) with 95% confidence intervals (CIs) were calculated using random‐effects models. Three publications reporting four RCTs involving 1154 patients were included, with 752 receiving delgocitinib and 402 receiving vehicle. At week 16, treatment success was significantly higher with delgocitinib (RR 3.17; 95% CI 1.78–5.65; p < 0.01), corresponding to an absolute risk difference of 16.9% and a number needed to treat (NNT) of 6 (95% CI 3–16). Similar results at weeks 4 and 8. Delgocitinib also led to significantly greater improvements in HESD itch and pain scores. No significant differences were found in overall adverse events (AEs), treatment‐related AEs, or serious AEs. Discontinuation due to AEs was lower in the delgocitinib group. Delgocitinib 20–30 mg/g demonstrated greater efficacy than vehicle and a favourable safety profile, supporting its use as a topical treatment for CHE.
- Open Access
- 2 August 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (8) , 1868
IL-15/IL-15Rα in SJS/TEN: Relevant Expression of IL15 and IL15RA in Affected Skin
Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening hypersensitivity reaction to medications characterized by keratinocyte apoptosis and skin detachment. IL-15 serum levels have been associated with severity and prognosis of SJS/TEN. We have measured IL-15 concentrations in serum and blister fluid (BF) from patients with SJS/TEN by ELISA and used quantitative RT-PCR to analyze the expression of IL15 and IL15RA (encoding for IL-15 Receptor-α chain) genes in peripheral blood and BF cells, including isolated monocytes, and in affected skin. A positive correlation was found between IL-15 serum levels and a percent of detached skin. BF concentrations were higher, but no correlation was found. Higher IL15 and IL15RA gene expression levels were found in skin-infiltrating blister fluid cells compared to peripheral mononuclear cells. Moreover, IL15RA transcripts were barely detected in healthy skin, being the highest expression levels found in samples from two SJS/TEN patients who did not survive. The cutaneous expression of IL-15Rα in SJS/TEN may provide an explanation to the tissue-specific immune cytotoxic response in this clinical entity, and the results suggest that the effects of IL-15 in SJS/TEN patients may be dependent on the expression of its private receptor IL-15Rα in affected skin.
- 2 August 2022
- Published by MDPI AG in Biomedicines
- Vol. 10 (8) , 1868
Open AccessIL-15/IL-15Rα in SJS/TEN: Relevant Expression of IL15 and IL15RA in Affected Skin
Stevens–Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening hypersensitivity reaction to medications characterized by keratinocyte apoptosis and skin detachment. IL-15 serum levels have been associated with severity and prognosis of SJS/TEN. We have measured IL-15 concentrations in serum and blister fluid (BF) from patients with SJS/TEN by ELISA and used quantitative RT-PCR to analyze the expression of IL15 and IL15RA (encoding for IL-15 Receptor-α chain) genes in peripheral blood and BF cells, including isolated monocytes, and in affected skin. A positive correlation was found between IL-15 serum levels and a percent of detached skin. BF concentrations were higher, but no correlation was found. Higher IL15 and IL15RA gene expression levels were found in skin-infiltrating blister fluid cells compared to peripheral mononuclear cells. Moreover, IL15RA transcripts were barely detected in healthy skin, being the highest expression levels found in samples from two SJS/TEN patients who did not survive. The cutaneous expression of IL-15Rα in SJS/TEN may provide an explanation to the tissue-specific immune cytotoxic response in this clinical entity, and the results suggest that the effects of IL-15 in SJS/TEN patients may be dependent on the expression of its private receptor IL-15Rα in affected skin.
- 1 June 2022
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (6) , 699-701
Response of Darier Disease Following Treatment With Baricitinib
This case report describes a middle-aged woman with a long-standing papular eruption that affected the scalp, chest, forearms, and skin folds.
- 1 June 2022
- Published by American Medical Association (AMA) in JAMA Dermatology
- Vol. 158 (6) , 699-701
Response of Darier Disease Following Treatment With Baricitinib
This case report describes a middle-aged woman with a long-standing papular eruption that affected the scalp, chest, forearms, and skin folds.
- Open Access
- 26 April 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (8) , E489-E491
Pityriasis rosea, COVID‐19 and vaccination: new keys to understand an old acquaintance
- 26 April 2021
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 35 (8) , E489-E491
Open AccessPityriasis rosea, COVID‐19 and vaccination: new keys to understand an old acquaintance